New Ray Medicine International Holding Limited (HKG:2908)

Market Cap	66.87M
Revenue (ttm)	93.95M
Net Income (ttm)	-31.01M
Shares Out	n/a
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,800
Average Volume	222,187
Open	0.4050
Previous Close	0.4050
Day's Range	0.4000 - 0.4050
52-Week Range	0.3750 - 0.4600
Beta	n/a
RSI	n/a
Earnings Date	Aug 27, 2025

About R1 RCM

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor rel...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2001
• Employees: 29
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2908

Financial Performance

In 2024, HKG:2908's revenue was 93.95 million, an increase of 87.31% compared to the previous year's 50.15 million. Losses were -31.01 million, 39.9% more than in 2023.